Skip to content

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Early Time Course of Symptom Improvement With Remibrutinib in Chronic Spontaneous Urticaria: Pooled Post Hoc Analyses of the REMIX-1/2 Phase 3 Studies.

We undertook a post hoc, sponsor‐funded analysis of data from two recent clinical trials in CSU. Remibrutinib numerically improved CSU symptoms at 12 h; meaningful effects persisted from Day‐2 through Week‐52.

Gordon Sussman, N. Chapman-Rothe, Tao Ding et al. · 0 citations
Open access Oct 2026

Oral deucrictibant for on-demand treatment of hereditary angioedema attacks: a phase 3, multicentre, randomised, double-blind, placebo-controlled crossover trial.

The use of deucrictibant as potentially the first orally administered bradykinin B2 receptor antagonist for the treatment of attacks of bradykinin-mediated angioedema, including hereditary angioedema, is supported and may address an unmet need for options that are effective and well tolerated, with convenient administr...

Marc A. Riedl, P. Li, A. Adatia et al. · 1 citation
Review Open access Sep 2026

Management of chronic urticaria: Current status and future prospect.

Chronic urticaria is a mast cell-driven inflammatory disease characterized by recurrent wheals, angioedema or both for more than 6 weeks, with substantial effects on sleep, quality of life, mental health and daily functioning. Type I autoallergic and type IIb autoimmune mechanisms represent major endotypes, but many pa...

A. Salman, M. Al-Ahmad, M. Al-Nesf et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.